Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Carolina Moretti is active.

Publication


Featured researches published by Carolina Moretti.


International Journal of Cardiology | 2013

Acute kidney injury following transcatheter aortic valve implantation: incidence, predictors and clinical outcome

Francesco Saia; Cristina Ciuca; Nevio Taglieri; Cinzia Marrozzini; Carlo Savini; Barbara Bordoni; Gianni Dall'Ara; Carolina Moretti; Emanuele Pilato; Sofia Martin-Suarez; Francesco Dimitri Petridis; Roberto Di Bartolomeo; Angelo Branzi; Antonio Marzocchi

BACKGROUND Limited data exist on renal complications of transcatheter aortic valve implantation (TAVI) within a comprehensive program using different valves with transfemoral, transapical, and trans-subclavian approach. METHODS Prospective single-center registry of 102 consecutive patients undergoing TAVI using both approved bioprostheses and different access routes. The main objective was to assess the incidence, predictors and the clinical impact of acute kidney injury (AKI). AKI was defined according to the valve academic research consortium (VARC) indications. RESULTS Mean age was 83.7 ± 5.3 years, logistic EuroSCORE 22.6 ± 12.4%, and STS score 8.2 ± 4.1%. Chronic kidney disease at baseline was present in 87.3%. Periprocedural AKI developed in 42 patients (41.7%): 32.4% stage 1, 4.9% stage 2 and 3.9% stage 3. The incidence of AKI was 66.7% in transapical, 30.3% in transfemoral, and 50% in trans-subclavian procedures. The only independent predictor of AKI was transapical access, with a hazard ratio (HR) between 4.57 and 5.18 based on the model used. Cumulative 1-year survival was 88.2%. At Cox regression analysis, the only independent predictor of 30-day mortality was diabetes mellitus (HR 7.05, 95% CI 1.07-46.32; p=0.042), whilst the independent predictors of 1-year death were baseline glomerular filtration rate<30 mL/min (HR 5.74, 95% CI 1.42-23.26; p=0.014) and post-procedural AKI 3 (HR 8.59, 95% CI 1.61-45.86, p=0.012). CONCLUSIONS TAVI is associated with a high incidence of AKI. Although in the majority of the cases AKI is of mild entity and reversible, AKI 3 holds a strong negative impact on 1-year survival. The incidence of AKI is higher with transapical access.


Eurointervention | 2011

The role of percutaneous balloon aortic valvuloplasty as a bridge for transcatheter aortic valve implantation.

Francesco Saia; Cinzia Marrozzini; Carolina Moretti; Cristina Ciuca; Nevio Taglieri; Barbara Bordoni; Gianni Dall'Ara; Alessi L; Lanzillotti; Bacchi-Reggiani Ml; Branzi A; Antonio Marzocchi

AIMS Many inoperable patients with severe aortic stenosis (AS) are not immediately eligible for transcatheter aortic valve implantation (TAVI). We evaluated the role of percutaneous balloon aortic valvuloplasty (BAV) in this setting. METHODS AND RESULTS Among 210 consecutive patients referred to our institution for BAV, we identified three groups: immediately eligible for TAVI (n=65, 31%), excluded from TAVI (n=67, 32%), BAV as a bridge to TAVI (n=78, 37%). This last group comprised patients with low left ventricular ejection fraction, frailty or enfeebled status, symptoms of uncertain origin, critical conditions, moderate-to-severe mitral valve regurgitation, need of major non-cardiac surgery. Outpatient clinic visit and echocardiography were performed around one month after BAV to decide the final therapeutic strategy. Mean age was 81±8 years and the vast majority of patients had comorbidities and high-risk features. The incidence of periprocedural adverse events was 6.4%: 5.1% death (four patients: one procedural complication, three, natural disease progression), 1.3% minor stroke. After BAV, 46% of these patients were deemed eligible for TAVI, and 28% for cardiac surgery. Patients who underwent TAVI after bridge BAV showed 94% 30-day survival. CONCLUSIONS BAV is a safe and effective tool to bridge selected patients to TAVI when indications are not obvious.


Eurointervention | 2013

Emerging indications, in-hospital and long-term outcome of balloon aortic valvuloplasty in the transcatheter aortic valve implantation era.

Francesco Saia; Cinzia Marrozzini; Cristina Ciuca; Nevio Taglieri; Tullio Palmerini; Barbara Bordoni; Carolina Moretti; Gianni Dall'Ara; Angelo Branzi; Antonio Marzocchi

AIMS The introduction of transcatheter aortic valve implantation (TAVI) has generated a renewed interest in the treatment of high-risk patients with severe aortic stenosis. This study describes the indications and long-term outcome of balloon aortic valvuloplasty (BAV) in recent years. METHODS AND RESULTS Between 2000 and 2010, 415 consecutive patients at our institution underwent BAV. The number of BAV per year increased sharply after the introduction of TAVI. Patients were 77.5±10.9 years old and showed important comorbidities (average logistic EuroSCORE=23.9±15.3%). We identified four cohorts according to the indications: 1) bridge for TAVI (B-TAVI; n=162); 2) bridge for aortic valve replacement (B-AVR, n=97); 3) cardiogenic shock (n=23); 4) palliation (n=133). Baseline characteristics were significantly different among groups. In-hospital mortality was 5.1%, and occurred predominantly in patients who underwent BAV in the setting of cardiogenic shock (56.5% vs. around 2% in the other subgroups). Other major events were stroke (0.5%), major vascular complications (2.2%), and life-threatening bleedings (1.5%). The cumulative one-year and two-year mortality rates were 33.2% and 57.4%, respectively, with the highest incidence in the shock group (70.7% and 80.4%) and the lowest in the B-AVR group (21.7% and 38.4%). Rehospitalisation for heart failure was 26.3% at one-year and 47.2% at two-year follow-up. CONCLUSIONS The number of BAV is increasing, mainly due to increased referral of high-risk patients and to the emerging indication of bridge for TAVI. In this complex population, BAV is relatively safe but two-year survival remains poor, and more effective and definitive treatments should be pursued in a timely fashion.


Circulation | 2016

Transcatheter Tricuspid Valve-in-Valve Implantation for the Treatment of Dysfunctional Surgical Bioprosthetic Valves: An International, Multicenter Registry Study.

Doff B. McElhinney; Allison K. Cabalka; Jamil Aboulhosn; Andreas Eicken; Younes Boudjemline; Stephan Schubert; Dominique Himbert; Jeremy D. Asnes; Stefano Salizzoni; Martin L. Bocks; John P. Cheatham; Tarek S. Momenah; Dennis W. Kim; Dietmar Schranz; Jeffery Meadows; John Thomson; Bryan H. Goldstein; Ivory Crittendon; Thomas E. Fagan; John G. Webb; Eric Horlick; Jeffrey W. Delaney; Thomas K. Jones; Shabana Shahanavaz; Carolina Moretti; Michael R. Hainstock; Damien Kenny; Felix Berger; Charanjit S. Rihal; Danny Dvir

Background— Off-label use of transcatheter aortic and pulmonary valve prostheses for tricuspid valve-in-valve implantation (TVIV) within dysfunctional surgical tricuspid valve (TV) bioprostheses has been described in small reports. Methods and Results— An international, multicenter registry was developed to collect data on TVIV cases. Patient-related factors, procedural details and outcomes, and follow-up data were analyzed. Valve-in-ring or heterotopic TV implantation procedures were not included. Data were collected on 156 patients with bioprosthetic TV dysfunction who underwent catheterization with planned TVIV. The median age was 40 years, and 71% of patients were in New York Heart Association class III or IV. Among 152 patients in whom TVIV was attempted with a Melody (n=94) or Sapien (n=58) valve, implantation was successful in 150, with few serious complications. After TVIV, both the TV inflow gradient and tricuspid regurgitation grade improved significantly. During follow-up (median, 13.3 months), 22 patients died, 5 within 30 days; all 22 patients were in New York Heart Association class III or IV, and 9 were hospitalized before TVIV. There were 10 TV reinterventions, and 3 other patients had significant recurrent TV dysfunction. At follow-up, 77% of patients were in New York Heart Association class I or II (P<0.001 versus before TVIV). Outcomes did not differ according to surgical valve size or TVIV valve type. Conclusions— TVIV with commercially available transcatheter prostheses is technically and clinically successful in patients of various ages across a wide range of valve size. Although preimplantation clinical status was associated with outcome, many patients in New York Heart Association class III or IV at baseline improved. TVIV should be considered a viable option for treatment of failing TV bioprostheses.


American Heart Journal | 2014

Causes and timing of death during long-term follow-up after transcatheter aortic valve replacement.

Francesco Saia; Azeem Latib; Cristina Ciuca; Valeria Gasparetto; Massimo Napodano; Alessandro Sticchi; Laura Anderlucci; Cinzia Marrozzini; Toru Naganuma; Ottavio Alfieri; Michela Facchin; Brunilda Hoxha; Carolina Moretti; Antonio Marzocchi; Antonio Colombo; Giuseppe Tarantini

BACKGROUND Transcatheter aortic valve replacement (TAVR) is an effective therapeutic option for patients with severe aortic stenosis at high risk for surgery. Identification of causes of death after TAVR may help improve patient selection and outcome. METHODS We enrolled 874 consecutive patients who underwent TAVR at 3 centers using all approved bioprostheses and different access routes. Clinical outcomes during follow-up were defined according to the Valve Academic Research Consortium 2 definitions. Causes of deaths were carefully investigated. RESULTS Mean logistic European System for Cardiac Operative Risk Evaluation was 23.5% ± 15.3%; Society of Thoracic Surgery score, 9.0% ± 8.2%. The Corevalve (Medtronic, Minneapolis, MN) was used in 41.3%; the Edwards Sapien (Edwards Lifesciences Inc., Irvine, CA) in 57.3%. Vascular access was transfemoral in 75.7%. In-hospital mortality was 5.0%. Cumulative mortality rates at 1 to 3 years were 12.4%, 23.4%, and 31.5%, respectively. Landmark analysis showed a significantly higher incidence of cardiovascular (CV) death in the first 6 months of follow-up and a significantly higher incidence of non-CV death thereafter. At Cox regression analysis, the independent predictors of in-hospital mortality were acute kidney injury grades 2 to 3 (hazard ratio [HR] 3.41) life-threatening bleeding (HR 4.26), major bleeding (HR 4.61), and myocardial infarction (HR 3.89). The independent predictors of postdischarge mortality were chronic obstructive pulmonary disease (HR 1.48), left ventricular ejection fraction at discharge (HR 0.98), and glomerular filtration rate <30 mL/min per 1.73 m(2) (HR 1.64). CONCLUSIONS Around a third of patients treated with TAVR in daily practice die within the first 3 years of follow-up. Early mortality is predominantly CV, whereas late mortality is mainly non-CV, and it is often due to preexisting comorbidity.


International Journal of Cardiology | 2012

Residual aortic regurgitation is a major determinant of late mortality after transcatheter aortic valve implantation.

Pedro A. Lemos; Francesco Saia; José Mariani; Cinzia Marrozzini; Antonio Esteves Filho; Luiz Junya Kajita; Cristina Ciuca; Nevio Taglieri; Barbara Bordoni; Carolina Moretti; Tullio Palmerini; Marianna D. A. Dracoulakis; Fabio Biscegli Jatene; Roberto Kalil-Filho; Antonio Marzocchi

aortic valve implantation Pedro A. Lemos ⁎, Francesco Saia , Jose Mariani Jr., Cinzia Marrozzini , Antonio Esteves Filho , Luiz J. Kajita , Cristina Ciuca , Nevio Taglieri , Barbara Bordoni , Carolina Moretti , Tullio Palmerini , Marianna D.A. Dracoulakis , Fabio B. Jatene , Roberto Kalil-Filho , Antonio Marzocchi c a Sirio-Libanes Hospital, Sao Paulo, Brazil b Heart Institute, University of Sao Paulo Medical School, Sao Paulo, Brazil c Institute of Cardiology, University of Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy d Irmandade da Santa Casa de Misericordia, Sao Paulo, Brazil


Future Cardiology | 2011

Incidence, prognostic value and management of vascular complications with transfemoral transcatheter aortic valve implantation

Francesco Saia; Barbara Bordoni; Cinzia Marrozzini; Cristina Ciuca; Carolina Moretti; Angelo Branzi; Antonio Marzocchi

Inoperable or high-risk patients with severe aortic stenosis who undergo transcatheter aortic valve implantation (TAVI) have better outcomes compared with those treated with standard medical therapy. As for any other invasive procedure, peri-procedural complications may occur, reducing the procedural success rate and potentially affecting short- and mid-term outcomes. The transfemoral approach prevails over other possible access-site options in most registries. The use of large introducer sheaths and the need for double arterial vascular access can lead to higher rates of vascular complications in this elderly population, with a high prevalence of baseline peripheral artery disease. In this article, we review the results of recent clinical trials and major registries using the two different bioprosthesis currently available for TAVI, focusing on access site-related complications with transfemoral TAVI, their management and relationship with in-hospital and 30-day survival. Awareness of the mechanisms behind these complications might help in their prevention, recognition and management and may ultimately improve the clinical outcome of TAVI procedures.


Catheterization and Cardiovascular Interventions | 2017

Incidence, treatment, and outcome of acute aortic valve regurgitation complicating percutaneous balloon aortic valvuloplasty

Gianni Dall'Ara; Francesco Saia; Carolina Moretti; Cinzia Marrozzini; Nevio Taglieri; Barbara Bordoni; Matteo Chiarabelli; Cristina Ciuca; Claudio Rapezzi; Antonio Marzocchi

To evaluate the incidence, treatment, and outcomes of acute aortic regurgitation (ARR) complicating BAV.


Circulation | 2016

Transcatheter Tricuspid Valve-in-Valve Implantation for the Treatment of Dysfunctional Surgical Bioprosthetic Valves

Doff B. McElhinney; Allison K. Cabalka; Jamil A Aboulhosn; Andreas Eicken; Younes Boudjemline; Stephan Schubert; Dominique Himbert; Jeremy D. Asnes; Stefano Salizzoni; Martin L. Bocks; John P. Cheatham; Tarek S. Momenah; Dennis W. Kim; Dietmar Schranz; Jeffery Meadows; John Thomson; Bryan H. Goldstein; Ivory Crittendon; Thomas E. Fagan; John G. Webb; Eric Horlick; Jeffrey W. Delaney; Thomas K. Jones; Shabana Shahanavaz; Carolina Moretti; Michael R. Hainstock; Damien Kenny; Felix Berger; Charanjit S. Rihal; Danny Dvir

Background— Off-label use of transcatheter aortic and pulmonary valve prostheses for tricuspid valve-in-valve implantation (TVIV) within dysfunctional surgical tricuspid valve (TV) bioprostheses has been described in small reports. Methods and Results— An international, multicenter registry was developed to collect data on TVIV cases. Patient-related factors, procedural details and outcomes, and follow-up data were analyzed. Valve-in-ring or heterotopic TV implantation procedures were not included. Data were collected on 156 patients with bioprosthetic TV dysfunction who underwent catheterization with planned TVIV. The median age was 40 years, and 71% of patients were in New York Heart Association class III or IV. Among 152 patients in whom TVIV was attempted with a Melody (n=94) or Sapien (n=58) valve, implantation was successful in 150, with few serious complications. After TVIV, both the TV inflow gradient and tricuspid regurgitation grade improved significantly. During follow-up (median, 13.3 months), 22 patients died, 5 within 30 days; all 22 patients were in New York Heart Association class III or IV, and 9 were hospitalized before TVIV. There were 10 TV reinterventions, and 3 other patients had significant recurrent TV dysfunction. At follow-up, 77% of patients were in New York Heart Association class I or II (P<0.001 versus before TVIV). Outcomes did not differ according to surgical valve size or TVIV valve type. Conclusions— TVIV with commercially available transcatheter prostheses is technically and clinically successful in patients of various ages across a wide range of valve size. Although preimplantation clinical status was associated with outcome, many patients in New York Heart Association class III or IV at baseline improved. TVIV should be considered a viable option for treatment of failing TV bioprostheses.


Catheterization and Cardiovascular Interventions | 2012

Is balloon aortic valvuloplasty safe in patients with significant aortic valve regurgitation

Francesco Saia; Cinzia Marrozzini; Cristina Ciuca; Barbara Bordoni; Gianni Dall'Ara; Carolina Moretti; Nevio Taglieri; Tullio Palmerini; Angelo Branzi; Antonio Marzocchi

Objectives: To assess safety and effectiveness of balloon aortic valvuloplasty (BAV) in patients with symptomatic severe aortic stenosis (AS) and significant aortic regurgitation.

Collaboration


Dive into the Carolina Moretti's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge